You just read:

US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sézary Syndrome

News provided by

Kyowa Hakko Kirin Co. Ltd.

25 Aug, 2017, 07:30 BST